Advertisement
GSK vs PFE
Which Stock Would AI Choose? GlaxoSmithKline (GSK) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- GSK reported strong Q2 2026 core sales growth of 5% and reaffirmed full-year guidance, supported by specialty medicines and vaccines momentum.
- PFE raised its 2026 revenue guidance midpoint to $61.5 billion after Q2 results showed 18% operational growth in launched and acquired products.
- Recent analyst action favored GSK with a Berenberg upgrade to Buy and higher price target, citing pipeline progress and business development.
- Both companies maintain robust dividend programs, with GSK declaring a 17p quarterly dividend and PFE a $0.43 quarterly dividend.
- GSK's recent market activity reflects pipeline catalysts in oncology, while PFE emphasizes cost savings and non-COVID product expansion.
- Relative performance in recent weeks shows GSK benefiting from positive sentiment around upgrades, contrasting PFE's steadier but more muted price response.
Introduction
GlaxoSmithKline (GSK) and Pfizer (PFE) represent two established players in the global pharmaceuticals sector, each with diversified portfolios spanning specialty medicines, vaccines, and oncology. Investors and traders often compare these stocks to assess relative positioning amid evolving regulatory, competitive, and macroeconomic conditions. This analysis examines recent performance, business drivers, and market sentiment to provide context for those evaluating healthcare exposure. The comparison appeals particularly to portfolio managers seeking stability in large-cap pharma names and active traders monitoring sector rotation or catalyst-driven moves.
GSK Overview and Recent Performance
GSK operates as a science-led global healthcare company focused on specialty medicines, vaccines, and general medicines. In recent weeks, the stock has drawn attention from pipeline advancements and analyst commentary. Q2 2026 core results highlighted 5% sales growth to £8.4 billion, driven by specialty medicines (+14%) and vaccines (+8%), with HIV and oncology segments contributing notably. Guidance for the full year remains intact at 3-5% turnover growth and 7-9% core operating profit and earnings per share expansion. A September 20, 2026, Berenberg upgrade to Buy with a raised target of GBP 22 underscored confidence in business development deals and late-stage pipeline momentum, including oncology assets. Market activity in recent periods reflects these developments, with the U.S.-listed shares trading near USD 50 amid broader sector dynamics.
PFE Overview and Recent Performance
Pfizer develops and manufactures a broad range of biopharmaceutical products, including oncology, vaccines, and internal medicine therapies. Recent quarters have emphasized non-COVID revenue expansion and productivity measures. Q2 2026 revenues reached $15.0 billion, with launched and acquired products growing 18% operationally; the company raised full-year 2026 revenue guidance by $500 million at the midpoint to a range of $60.5-62.5 billion. Adjusted diluted earnings per share came in at $0.77. Cost-saving initiatives have expanded, targeting additional productivity gains through 2029. Pipeline updates include positive Phase 3 data for LITFULO in vitiligo and priority review for certain oncology combinations. In recent market activity, shares have traded around $27.66, showing resilience after earlier volatility, supported by dividend continuity at $0.43 per quarter.
Trending AI Robots
Tickeron’s Trending AI Robots page curates high-performing automated trading systems from a library of hundreds of AI trading bots that cover thousands of tickers. Only those demonstrating superior adaptability to prevailing market conditions earn placement in this section. Available bots exhibit varied annualized returns frequently exceeding 100%, with select agents achieving win rates between 59% and 67% and profit factors above 2.0 across different timeframes and strategies. These systems employ distinct approaches, including momentum, trend-following, and multi-ticker hedging, each with unique performance statistics and ticker universes. Traders interested in data-driven automation can explore the full selection on the platform.
Head-to-Head Comparison
GSK and PFE differ in portfolio emphasis and recent catalysts. GSK maintains a stronger focus on specialty medicines and vaccines, with recent pipeline news centered on oncology approvals and acquisitions supporting growth visibility into 2031. PFE balances a wider primary care and oncology footprint, leveraging acquired assets and cost discipline to drive non-COVID expansion. Momentum in recent weeks tilted toward GSK following the analyst upgrade, while PFE benefited from guidance raises but experienced more tempered price reaction. Risk factors include patent exposures—GSK navigating dolutegravir loss of exclusivity later this decade and PFE managing post-COVID normalization. Sector exposure remains comparable within healthcare, though GSK’s European listing introduces currency considerations versus PFE’s U.S. domicile. Market sentiment reflects GSK’s near-term catalyst flow against PFE’s established scale and dividend yield profile.
Tickeron AI Verdict
Based on observable factors such as recent trend consistency, analyst upgrades, and pipeline catalysts, Tickeron’s AI models would currently assign a modestly higher probabilistic preference to GSK over PFE. GSK’s combination of reaffirmed guidance, business development activity, and positive analyst reassessment provides clearer near-term momentum signals within the dataset. PFE demonstrates solid operational execution and guidance support, yet relative positioning favors GSK in the current window. This assessment reflects probabilistic modeling rather than certainty and should be weighed alongside individual risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and PFE is a Hold.
GSK in downward trend: price dove below 50-day moving average on September 22, 2026
GSK moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend. In 26 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 60%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In 40 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for GSK turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for GSK entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GSK's RSI Indicator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 57 cases where GSK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
Following a +1.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 203 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
GSK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.266) is normal, around the industry mean (19.199). P/E Ratio (15.948) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.037) settles around the average of (0.025) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 46 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
PFE's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PFE turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 24 of 43 cases over the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 46 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
Following a +2.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 149 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.922) is normal, around the industry mean (19.199). P/E Ratio (37.789) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). PFE has a moderately high Dividend Yield (0.060) as compared to the industry average of (0.025). P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 29 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
GSK | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 46 | 100 | |
SMR RATING 1..100 | 34 | 83 | |
PRICE GROWTH RATING 1..100 | 60 | 29 | |
P/E GROWTH RATING 1..100 | 56 | 5 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (5) in the Pharmaceuticals Major industry is in the same range as PFE (20). This means that GSK’s stock grew similarly to PFE’s over the last 12 months.
GSK's Profit vs Risk Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (100). This means that GSK’s stock grew somewhat faster than PFE’s over the last 12 months.
GSK's SMR Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (83). This means that GSK’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (29) in the Pharmaceuticals Major industry is in the same range as GSK (60). This means that PFE’s stock grew similarly to GSK’s over the last 12 months.
PFE's P/E Growth Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (56). This means that PFE’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | PFE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | 1 day ago 62% |
| Stochastic ODDS (%) | 1 day ago 65% | 1 day ago 50% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 53% |
| MACD ODDS (%) | 1 day ago 59% | 1 day ago 56% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 53% | 1 day ago 49% |
| Advances ODDS (%) | 8 days ago 63% | 3 days ago 54% |
| Declines ODDS (%) | 6 days ago 55% | 10 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 65% | 1 day ago 56% |
| Aroon ODDS (%) | 1 day ago 41% | 1 day ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green while PFE’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- GSK’s TA Score: 4 bullish, 5 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +1.81% price change this week, while PFE (@Pharmaceuticals: Major) price change was +4.32% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -3.74%. For the same industry, the average monthly price growth was -6.28%, and the average quarterly price growth was +2.55%.
Reported Earning Dates
GSK is expected to report earnings on Oct 28, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-3.74% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement